B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look

Gynecologic Oncology

Volumn 134, Issue 1, 2014, Pages 181-189

  Smith, Jenessa B ^b   Stashwick, Caitlin ^a   Powell, Daniel J ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B7 H4; Ovarian cancer; Targeted therapies

Indexed keywords

BLOCKING ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOTOXIN; MESSENGER RNA; OLIGONUCLEOTIDE; PROGRAMMED DEATH 1 RECEPTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

APOPTOSIS; AUTOIMMUNITY; CANCER CELL; CANCER IMMUNOTHERAPY; CARCINOGENESIS; GYNECOLOGIC CANCER; HUMAN; LYMPHOCYTE FUNCTION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

B7-H4; OVARIAN CANCER; TARGETED THERAPIES;

ANIMALS; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 84903170093     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.03.553     Document Type: Review

References (60)

1. A.C. Society Cancer Facts and Figs. 2014 [online]. Cancer Facts and Figures 2014 American Cancer Society Atlanta
2. A.C. Society Ovarian cancer: detailed guide [online] 2014
3. B.H. Nelson The impact of T-cell immunity on ovarian cancer outcomes Immunol Rev 222 2008 101 116 (Pubitemid 351430376)
4. B.J. Monk, D.C. Choi, G. Pugmire, and R.A. Burger Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer Gynecol Oncol 96 2005 902 905 (Pubitemid 40255525)
5. B.J. Monk, E. Pujade-Lauraine, and R.A. Burger Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease Ann Oncol 24 Suppl. 10 2013 x53 x58
6. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, and G. Regnani et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 2003 203 213 (Pubitemid 36077915)
7. W.T. Hwang, S.F. Adams, E. Tahirovic, I.S. Hagemann, and G. Coukos Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis Gynecol Oncol 124 2012 192 198
8. L. Zhang, H. Wu, D. Lu, G. Li, C. Sun, and H. Song et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus Oncogene 46 2013 5347 5358
9. S. Salceda, T. Tang, M. Kmet, A. Munteanu, M. Ghosh, and R. Macina et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation Exp Cell Res 306 2005 128 141 (Pubitemid 40692778)
10. C. Chen, Q.X. Qu, Y. Shen, C.Y. Mu, Y.B. Zhu, and X.G. Zhang et al. Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape Cancer Lett 317 2011 99 105
11. G.L. Sica, I.H. Choi, G. Zhu, K. Tamada, S.D. Wang, and H. Tamura et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity Immunity 18 2003 849 861 (Pubitemid 36776432)
12. X. Zang, P. Loke, J. Kim, K. Murphy, R. Waitz, and J.P. Allison B7x: a widely expressed B7 family member that inhibits T cell activation Proc Natl Acad Sci U S A 100 2003 10388 10392 (Pubitemid 37071888)
13. D.V. Prasad, S. Richards, X.M. Mai, and C. Dong B7S1, a novel B7 family member that negatively regulates T cell activation Immunity 18 2003 863 873 (Pubitemid 36776433)
14. J.D. Hansen, L. Du Pasquier, M.P. Lefranc, V. Lopez, A. Benmansour, and P. Boudinot The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective Mol Immunol 46 2009 457 472
15. I.H. Choi, G. Zhu, G.L. Sica, S.E. Strome, J.C. Cheville, and J.S. Lau et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family J Immunol 171 2003 4650 4654 (Pubitemid 37310581)
16. I. Kryczek, L. Zou, P. Rodriguez, G. Zhu, S. Wei, and P. Mottram et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma J Exp Med 203 2006 871 881
17. C. He, H. Qiao, H. Jiang, and X. Sun The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival Clin Dev Immunol 2011 2011 695834
18. B. Tringler, W. Liu, L. Corral, K.C. Torkko, T. Enomoto, and S. Davidson et al. B7-H4 overexpression in ovarian tumors Gynecol Oncol 100 2006 44 52 (Pubitemid 41815048)
19. B. Tringler, S. Zhuo, G. Pilkington, K.C. Torkko, M. Singh, and M.S. Lucia et al. B7-h4 is highly expressed in ductal and lobular breast cancer Clin Cancer Res 11 2005 1842 1848 (Pubitemid 40471848)
20. K.C. Mugler, M. Singh, B. Tringler, K.C. Torkko, W. Liu, and J. Papkoff et al. B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration Appl Immunohistochem Mol Morphol 15 2007 363 370 (Pubitemid 350307840)
21. Y. Qian, L. Shen, L. Cheng, Z. Wu, and H. Yao B7-H4 expression in various tumors determined using a novel developed monoclonal antibody Clin Exp Med 11 2011 163 170
22. Y. Qian, L. Shen, C. Xu, Z. Wu, N.H. Brockmeyer, and P. Altmeyer et al. Development of a novel monoclonal antibody to B7-H4: characterization and biological activity Eur J Med Res 16 2011 295 302
23. I. Simon, S. Zhuo, L. Corral, E.P. Diamandis, M.J. Sarno, and R.L. Wolfert et al. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer Cancer Res 66 2006 1570 1575 (Pubitemid 43259939)
24. D. Dangaj, E. Lanitis, A. Zhao, S. Joshi, Y. Cheng, and R. Sandaltzopoulos et al. Novel recombinant human B7-H4 antibodies overcome tumoral immune escape to potentiate T cell anti-tumor responses Cancer Res 73 2013 4820 4829
25. C. Chen, Q.X. Qu, Y. Shen, C.Y. Mu, Y.B. Zhu, and X.G. Zhang et al. Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape Cancer Lett 317 2012 99 105
26. I. Kryczek, S. Wei, L. Zou, G. Zhu, P. Mottram, and H. Xu et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells J Immunol 177 2006 40 44 (Pubitemid 43939113)
27. I. Kryczek, S. Wei, G. Zhu, L. Myers, P. Mottram, and P. Cheng et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma Cancer Res 67 2007 8900 8905 (Pubitemid 47437467)
28. S. Bellone, K. Watts, S. Cane, M. Palmieri, M.J. Cannon, and A. Burnett et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer Gynecol Oncol 98 2005 92 98 (Pubitemid 40826424)
29. J.R. Sedy, M. Gavrieli, K.G. Potter, M.A. Hurchla, R.C. Lindsley, and K. Hildner et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator Nat Immunol 6 2005 90 98 (Pubitemid 40136700)
30. X. Wang, J. Hao, D.L. Metzger, Z. Ao, L. Chen, and D. Ou et al. B7-H4 treatment of T cells inhibits ERK, JNK, p38, and AKT activation PLoS One 7 2012 e28232
31. D. Ou, X. Wang, D.L. Metzger, Z. Ao, P. Pozzilli, and R.F. James et al. Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway Cell Transplant 15 2006 399 410 (Pubitemid 44320506)
32. T. Azuma, G. Zhu, H. Xu, A.C. Rietz, C.G. Drake, and E.L. Matteson et al. Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data PLoS Med 6 2009 e1000166
33. J. Wei, P. Loke, X. Zang, and J.P. Allison Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity J Exp Med 208 2011 1683 1694
34. W.K. Suh, S. Wang, G.S. Duncan, Y. Miyazaki, E. Cates, and T. Walker et al. Generation and characterization of B7-H4/B7S1/B7x-deficient mice Mol Cell Biol 26 2006 6403 6411 (Pubitemid 44277881)
35. A.E. Krambeck, R.H. Thompson, H. Dong, C.M. Lohse, E.S. Park, and S.M. Kuntz et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival Proc Natl Acad Sci U S A 103 2006 10391 10396 (Pubitemid 44051177)
36. I. Simon, D. Katsaros, I. Rigault de la Longrais, M. Massobrio, A. Scorilas, and N.W. Kim et al. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression Gynecol Oncol 106 2007 334 341 (Pubitemid 47096655)
37. K. Yamaura, T. Watanabe, O. Boenisch, and M. Yeung et al. In vivo function of immune inhibitory molecule B7-H4 in alloimmune responses Am J Transplant 10 2010 355 362
38. L. Cheng, J. Jiang, R. Gao, S. Wei, F. Nan, and S. Li et al. B7-H4 expression promotes tumorigenesis in ovarian cancer Int J Gynecol Cancer 19 2009 1481 1486
39. Y.M. Abadi, H. Jeon, K.C. Ohaegbulam, L. Scandiuzzi, K. Ghosh, and K.A. Hofmeyer et al. Host b7x promotes pulmonary metastasis of breast cancer J Immunol 190 2013 3806 3814
40. J.M. Fauci, J.M. Straughn Jr., S. Ferrone, and D.J. Buchsbaum A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer Gynecol Oncol 2 2012 420 425
41. K. Oikonomopoulou, L. Li, Y. Zheng, I. Simon, R.L. Wolfert, and D. Valik et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel Br J Cancer 99 2008 1103 1113
42. J. Hamanishi, M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, and K. Yamaguchi et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci U S A 104 2007 3360 3365 (Pubitemid 46364164)
43. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, and P. Hwu et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
44. F.S. Hodi, M. Butler, D.A. Oble, M.V. Seiden, F.G. Haluska, and A. Kruse et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients Proc Natl Acad Sci U S A 105 2008 3005 3010 (Pubitemid 351723658)
45. S.Q. Sun, C.G. Jiang, Y. Lin, Y.L. Jin, and P.L. Huang Enhanced T cell immunity by B7-H4 downregulation in nonsmall-cell lung cancer cell lines J Int Med Res 40 2012 497 506
46. J. Madhumathi, and R.S. Verma Therapeutic targets and recent advances in protein immunotoxins Curr Opin Microbiol 15 2012 300 309
47. R.J. Kelly, E. Sharon, I. Pastan, and R. Hassan Mesothelin-targeted agents in clinical trials and in preclinical development Mol Cancer Ther 11 2012 517 525
48. J.A. Posey, M.B. Khazaeli, M.A. Bookman, A. Nowrouzi, W.E. Grizzle, and J. Thornton et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors Clin Cancer Res 8 2002 3092 3099 (Pubitemid 35155018)
49. C. Chen, Y.B. Zhu, Y. Shen, Y.H. Zhu, X.G. Zhang, and J.A. Huang Increase of circulating B7-H4-expressing CD68 + macrophage correlated with clinical stage of lung carcinomas J Immunother 35 2012 354 358
50. Q. Xue, X.Y. Luan, Y.Z. Gu, H.Y. Wu, G.B. Zhang, and G.H. Yu et al. The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity Stem Cells Dev 19 2010 27 38
51. Y. Aoki, K. Takakuwa, S. Kodama, K. Tanaka, M. Takahashi, and A. Tokunaga et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer Cancer Res 51 1991 1934 1939
52. K. Fujita, H. Ikarashi, K. Takakuwa, S. Kodama, A. Tokunaga, and T. Takahashi et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes Clin Cancer Res 1 1995 501 507
53. R.S. Freedman, and C.D. Platsoucas Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes Cancer Treat Res 82 1996 115 146
54. R.S. Freedman, A.P. Kudelka, J.J. Kavanagh, C. Verschraegen, C.L. Edwards, and M. Nash et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma Clin Cancer Res 6 2000 2268 2278 (Pubitemid 30399193)
55. G. Gross, T. Waks, and Z. Eshhar Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci U S A 86 1989 10024 10028 (Pubitemid 20030768)
56. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 2011 725 733
57. S.A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D.L. Porter, and S.R. Rheingold et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 2013 1509 1518
58. M.H. Kershaw, J.A. Westwood, L.L. Parker, G. Wang, Z. Eshhar, and S.A. Mavroukakis et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin Cancer Res 12 2006 6106 6115 (Pubitemid 44703776)
59. D. Song, Q. Ye, C. Carpenito, M. Poussin, L.P. Wang, and C. Ji et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) Cancer Res 13 2011 4617 4627
60. L.E. Kandalaft, D.J. Powell Jr., and G. Coukos A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer J Transl Med 10 2012 157